Document is current
Any future updates will be listed below
-
Authors
Schneider, Michael
Paruzzo, Luca https://orcid.org/0000-0002-6505-0194
Stella, Federico https://orcid.org/0000-0003-3401-1309
Noll, Julia Han https://orcid.org/0000-0003-3066-7378
Ho, Matthew https://orcid.org/0000-0001-7937-1557
Babatunde, Victor
Ho, Bianca
Devi, Pooja
Chong, Elise A. https://orcid.org/0000-0001-8895-1625
Barta, Stefan K.
Nasta, Sunita D.
Svoboda, Jakub
Carter, Jordan
Cook, Michael R.
Hossain, Nasheed M.
Thomas, Colin J.
Patel, Vrutti
de Souza, Vitor B.
Alkhatib, Mohannad H.
Li, Ziyu
Tan, Melody
Michener, Peter
Guruprasad, Puneeth
Imparato, Antonio
Carturan, Alberto
Porazzi, Patrizia https://orcid.org/0000-0002-1372-7482
Fraietta, Joseph A.
Schuster, Stephen J.
Maillard, Ivan
Ruella, Marco https://orcid.org/0000-0003-4301-5811
Landsburg, Daniel J. https://orcid.org/0000-0002-5077-4181
- License Information
-
More Information
Article History
Received: 3 August 2025
Accepted: 25 March 2026
First Online: 15 May 2026
Competing interests
: E.A.C. served as a consultant for AstraZeneca, Novartis, Beigene, KITE, and Juno/BMS and received research funding from AbbVie and Genentech/Roche. S.D.N. received research funding from Pharmacyclics, Roche, Rafael, and FortySeven/Gilead. J.S. received research funding from Incyte, Merck, and TG Therapeutics; reports consultancy for, and having received research funding from, Bristol Myers Squibb, Seagen Inc, Pharmacyclics, and AstraZeneca; reports consultancy for ADC Therapeutics, Adaptive, Atara, Genmab, and Imbrium. I.M. received research funding from Genentech and Regeneron, consulting fees from Gilead, Sanofi, and Vertex Therapeutics, and served on the scientific advisory board of Garuda Therapeutics. S.J.S. served as a consultant to AstraZeneca, BeiGene, Celgene, Genentech, Genmab, Fate Therapeutics, Roche, Incyte, Juno Therapeutics, Legend Biotech, Loxo Oncology, MorphoSys, Mustang Biotech, Nordic Nanovector, Novartis, and Regeneron; received research funding from AbbVie, Adaptive Biotechnologies, Celgene, DTRM, Genentech, Roche, Juno Therapeutics, Merck, Novartis, Incyte, Pharmacyclics, and TG Therapeutics; received honoraria from Celgene and Novartis; and holds patents related to CD19 CAR T cells and autologous co-stimulated T cells. J.A.F. has patents and intellectual property in T-cell-based cancer immunotherapy with royalties; funding from Tmunity Therapeutics and Danaher Corporation; consultancy with Retro Biosciences; scientific advisory board memberships with Cartography Bio, Shennon Biotechnologies Inc., CellFe Biotech, OverT Bio, Inc., and Tceleron Therapeutics, Inc. S.K.B. served as a consultant to Acrotech, Affimed, Kyowa Kirin, Daiichi Sankyo, Janssen, ONO Pharmaceutics, and Citius. M.R. has patents related to CD19 CAR T-cells; consults for GLG, Guidepoint, AbClon, Acera, Vittoria Bio; research funding received from AbClon, Oxford NanoImaging, Vittoria Biotherapeutics, CURIOX, and Beckman Coulter; scientific founder of Vittoria Biotherapeutics. J.D.L. received research funding from Curis, Takeda, and Triphase and served on the Board of Directors, advisory committees and data and safety monitoring board for Incyte, ADCT, Karyopharm and Morphosis. M.S., L.P., F.S., J.H.N., M.H., V.B., B.H., P.D., J.C., M.R.C., N.M.H., C.J.T., V.B.S, M.H.A., V.P., Z.L., M.T., P.M., P.G., A.I., A.C., and P.P. have no competing interests to declare.
